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Introduction 
Gastric cancer (GC) is the second leading cause of cancer-related mortalities worldwide, 
especially in Asian countries. In South Korea, the incidence of GC was the highest in 
2017 and GC ranked fourth among the causes of cancer-related deaths [1-4]. Despite ad-
vances in therapeutics, recurrence occurs in about half of the patients, and the prognosis 
of recurrent and metastatic GC is very poor [5-7]. Thus, new therapeutic strategies in-
volving for tumor-specific molecular targets are critically needed to improve the outcome 
of recurrent and metastatic GC patients. Paclitaxel, which is one of the most commonly 
used standard chemotherapeutic drugs, binds to β-tubulin and stabilizes microtubules, 
resulting in G2/M arrest and cell death. Various targeted anticancer agents were tested in 
combination with paclitaxel as second-line therapy for advanced GC [8-11]. However, 
most combinations, except that with ramucirumab, failed to show improved efficacy [12]. 
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BET inhibitor, as an epigenetic regulator inhibitor, reduces the expression of oncogenes 
such as Myc and Bcl-2, which affects cancer growth and development. However, it has 
modest activity because of the narrow therapeutic index. Therefore, combination therapy is 
necessary to increase the anti-tumor effect. Paclitaxel, an anti-mitotic inhibitor, is used as 
second-line therapy for gastric cancer (GC) as a monotherapy or combination. In this study, 
we performed RNA sequencing of GC cells treated with iBET-151 and/or paclitaxel to iden-
tify the differentially expressed genes associated with possible mechanisms of synergistic 
effect. We also performed Gene Ontology enrichment and Kyoto Encyclopedia of Genes 
and Genomes pathway analyses to determine the most enriched terms and pathways of 
upregulated and downregulated genes. We found 460 genes in which iBET-151 and pacli-
taxel combination treatment changed more than single-treatment or no-treatment. Thus, 
additional functional studies are needed, but our results provide the first evidence of the 
synergistic effect between iBET-151 and paclitaxel in regulating the transcriptome of GC 
cells. 
Keywords: BET inhibitor, combination, differentially expressed genes, gastric cancer, pacli-
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Moreover, mechanisms underlying paclitaxel activity, except mito-
sis inhibition, have not yet been studied well. Elucidating these 
mechanisms is important for the selection of appropriate combi-
nation partners of paclitaxel.  
Epigenetic dysregulation is a common feature of cancer, includ-
ing GC. Eventually, it contributes to GC development and pro-
gression [13]. In our previous study, iBET-151, an inhibitor of the 
bromodomain and extraterminal (BET) protein, which is an epi-
genetic regulator, was found to function effectively in GC cells 
(unpublished data). A recent study reported that lowering the ex-
pression of B-cell lymphoma (BCL)-2 and BCL-xL, the targets of 
the BET protein, induces sensitivity to paclitaxel [14]. We con-
firmed that paclitaxel and iBET-151 exerted synergistic effects in 
GC cells by investigating cell viability and migration and the cell 
cycle (unpublished data). However, to determine the detailed syn-
ergistic mechanisms of paclitaxel and iBET-151, it is necessary to 
identify the overall changes in the transcriptome and associated 
pathways. 
RNA sequencing (RNA-seq), via next-generation sequencing, 
is very useful for differential expression analysis involving specific 
conditions, such as ‘drug treatment versus no-treatment.’ There-
fore, researchers can comprehensively report the gene expression 
changes related to drug treatment by performing RNA-based ge-
nome-wide profiling [15]. 
In this study, we performed RNA-seq to analyze the differential-
ly expressed genes (DEGs) observed following treatment with pa-
clitaxel, iBET-151, and their combination in GC cells. We also 
identified the biological and functional pathways associated with 
DEGs using the Gene Ontology (GO) and Kyoto Encyclopedia of 
Genes and Genomes (KEGG) databases to determine the possi-
ble action mechanisms of BET monotherapy and BET-paclitaxel 
combination treatment.  
Methods 
Cell line and cell culture 
AGS GC cell line (CRL-1739) was obtained from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). AGS cells 
were cultured in Eagle's Minimum Essential Medium supplement-
ed with 10% fetal bovine serum (Lonza, Basel, Switzerland) and 
1 ×  penicillin/streptomycin (Lonza). All experiments were per-
formed after AGS cells reached the exponential growth phase. 
Drugs 
A small-molecule inhibitor of the BET family, iBET-151, was pur-
chased from Selleckchem (Houston, TX, USA) and prepared as a 
10-mM stock solution in DMSO (Sigma-Aldrich, St. Louis, MO, 
USA). Paclitaxel, an anti-mitotic drug, was purchased from Sig-
ma-Aldrich. 
RNA-seq data analysis 
For differential expression analysis by RNA-seq, total RNA was 
isolated from iBET-151- or/and paclitaxel-treated or untreated 
AGS cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany), 
according to the manufacturer's instructions. RNA quantity and 
integrity were assessed using both Nanodrop and Bioanalyzer, ac-
cording to the manufacturer’s instructions. Library preparation 
and RNA-seq was performed using the Illumina TruSeq RNA Li-
brary Preparation Kit (Illumina, San Diego, CA, USA), according 
to the manufacturer’s protocol. Samples were sequenced on the Il-
lumina NovaSeq 6000, 150 bp paired-end reads, to a minimum 
depth of 120 million reads per sample. Sequenced reads were 
aligned to the hg19 genome assembly using TopHat2. Differential 
expression analysis was processed following the Tuxedo protocol. 
DEGs were defined based on the cutoff values of p ≤  0.05, false 
discovery rate <  0.05, and fold change (FC) >  1.5. The reference 
annotation based on Ensembl release 69 (ftp://ftp.ensembl.org/
pub/release-69/gtf/macaca_mulatta). 
Functional enrichment analysis 
GO annotation enrichment analysis was performed using The Da-
tabase for Annotation, Visualization, and Integrated Discovery 
(DAVID) (v6.8), an online tool applied for functional annotation 
analysis and Gene Set Enrichment Analysis using MSigDB. GO 
and KEGG pathway analyses provide a comprehensive set of func-
tional annotation tools for identifying characteristic biological at-
tributes of high-throughput genome or transcriptome data. 
Western blot analysis 
To study the effect of drugs on protein expression, tissues and cells 
were lysed in RIPA buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 
1% NP-40, 0.1% sodium dodecyl sulfate, 1 mM EDTA, 10% glyc-
erol) containing protease and phosphatase inhibitors (Roche Di-
agnostics, Laval, QC, Canada). The cell lysates were subjected to 
sodium dodecyl sulfate polyacrylamide gel electrophoresis and 
western blotting. Membranes were then developed using an en-
hanced chemiluminescence (ECL) reagent (GE Healthcare, Pisca-
taway, NJ, USA). α-tubulin was used as a loading control. Antibod-
ies used for western blotting included anti‒epidermal growth factor 
receptor (EGFR), anti‒fibroblast growth factor receptor (FGFR)-
3, and anti‒insulin-like growth factor-1 receptor (IGF-1R; Cell 
Signaling Technology, Beverly, MA, USA); anti‒human epidermal 
growth factor receptor (HER)-2, anti–HER-3, and anti-MET 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-α-tubulin 
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(Sigma-Aldrich); and horseradish peroxidase-conjugated second-
ary anti-rabbit and anti-mouse ( Jackson ImmunoResearch Labo-
ratories, West Grove, PA, USA) antibodies. Membranes were then 
developed using the ECL reagent (GE Healthcare), and α-tubulin 
was used as a loading control. Quantification was performed with 
a Molecular Imager ChemiDoc XRS+ Imaging System (Bio-Rad, 
Hercules, CA, USA) 
Statistical analysis 
Graphing was performed using GraphPad Prism software version 
8 (Graph Pad Software Inc., San Diego, CA, USA). All statistical 
analyses were performed using SPSS version 25 (IBM Corp., Ar-
monk, NY, USA). All the significance levels were set at p ≤  0.05, 
and all p-values were two-sided. 
Results 
DEGs induced by iBET-151, paclitaxel, and combination 
treatments 
In our previous study, we confirmed that iBET-151-paclitaxel 
combination treatment exerted a synergistic effect on cell viability 
and invasion in several cell lines (unpublished data). To under-
stand the effects of iBET-151 and paclitaxel on the whole tran-
scriptome better, we performed RNA-seq of AGS cells that were 
most affected by the synergistic effects of iBET-151 and paclitaxel 
to compare the global gene expression profiles of untreated and 
iBET-151-, paclitaxel-, and iBET-151–paclitaxel combina-
tion-treated cells. 
About 16,000 genes were selected after the preprocessing step, 
during which genes that were not detected in both treated and un-
treated AGS cells were excluded. Based on our DEG-specific crite-
ria, we observed that iBET-151 upregulated 239 genes, whereas 
paclitaxel upregulated 203 genes (Fig. 1A). Upregulation of 270 
genes by combination treatment was mainly due to the effect of 
iBET-151 treatment (Fig. 1A). Of the genes upregulated by iBET-
151 alone, 61% (167/270) were upregulated by the combination 
of iBET-151 and paclitaxel. Thus, these genes were shared be-
tween the combination- and iBET-151‒treated cells. 
Then, we observed that iBET-151 downregulated 395 genes, 
whereas paclitaxel downregulated 57 genes (Fig. 1B). In the com-
bination-treated cells, 358 genes were downregulated; among 
them, 73% (263/358) overlapped with the downregulated genes 
in the iBET-151‒treated cells (Fig. 1B). However, the genes regu-
lated by paclitaxel alone did not overlap with those regulated by 
iBET-151 alone or the iBET-151-paclitaxel combination. The top 
10 genes upregulated and downregulated by iBET-151, paclitaxel, 
and combination treatments are shown in Tables 1 and 2, respec-
tively.  
GO functional enrichment analysis  
To determine the biological effects of gene expression changes, we 
performed GO analysis with the selected DEGs using DAVID 
v6.8. Volcano plots were used for the concurrent demonstration of 
both FC and p-value of DEGs in mono- or combination-treated 
cells (Figs. 2A, 3A, and 4A). 
Interestingly, GO analysis showed that upregulated genes in 
iBET-151‒treated cells were most enriched in the chromatin si-








Fig. 1. Overview of genes regulated by iBET-151, paclitaxel, and combination treatments. (A) Venn diagram analysis of the number of 
upregulated genes in treated versus untreated cells is shown. (B) Venn diagram analysis of the number of downregulated genes in treated 
versus untreated cells is shown.
3 / 11https://doi.org/10.5808/GI.2020.18.4.e37
Genomics & Informatics 2020;18(4):e37
Table 1. Top 10 upregulated genes in AGS cells treated by iBET-151 and paclitaxel
Gene name Fold change p-value Function
iBET-151
EFR3B 5.880 0.0007 Membrane-anchoring component
GPR157 5.380 0.0415 Cell surface receptor signaling pathway, G-protein coupled receptor signaling pathway
STK31 4.980 0.0272 RNA catabolic process
IGFN1 4.440 0.0409 Cytokine-mediated signaling pathway, response to lipopolysaccharide, regulation of synapse organization
IL10RA 4.330 0.0111 Cytokine-mediated signaling pathway, response to lipopolysaccharide, regulation of synapse organization
CLUL1 4.180 0.0228 Cell death
SPOCK2 4.140 0.0484 Positive regulation of cell-substrate adhesion
TEX14 4.080 0.0392 Mitotic spindle assembly checkpoint
HIST2H4A 3.980 0.0046 Chromatin silencing at rDNA, negative regulation of gene expression (epigenetic)
CLU 3.920 0.0002 Release of cytochrome c from mitochondria, intrinsic apoptotic signaling pathway
Paclitaxel
BMP7 86.2229 0.0465 Secreted ligand of the TGF-beta
KCNQ5 43.4113 0.04195 Regulating potassium channel
AMPD3 34.5353 0.00245 Catalyzes the deamination of AMP to IMP in red cells and plays an important role in the purine nucleotide cycle.
TSPAN32 29.6508 0.00115 Functional roles in cell motility, membrane fusion, proliferation, and adaptive immunity
MAGED1 27.0958 0.0111 Inhibits cell cycle progression, and facilitates NGFR-mediated apoptosis
MYO15A 25.4572 0.0014 Actin-based motor molecules with ATPase activity
ZDHHC1 20.3930 0.04455 Innate immune response, related to phencyclidine abuse
CATSPERE 18.0009 0.01695 Calcium channel pore-forming proteins
ADCY10P1 12.9960 0.0478 Sphingosine metabolic process
MYLK 11.4716 0.0186 Activated by the binding of calcium-calmodulin, interaction with actin filaments to produce contractile activity
Combination
EFR3B 55.7152 0.0003 Acts as the membrane-anchoring component
MMP1 42.8137 0.0024 Calcium ion binding and metallopeptidase activity
HIST1H2BJ 32.0000 0.0362 Wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA 
as a template
SELENOM 22.0087 0.02955 Function as a thiol-disulfide oxidoreductase that participates in disulfide bond formation
HIST2H4A 20.2521 0.0042 Wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA 
as a template
TEX14 19.0273 0.035 Kinetochore-microtubule attachment during mitosis
HIST1H2BC 17.5087 0.04265 Wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA 
as a template
HIST1H2BG 17.2677 0.0098 Wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA 
as a template
plex (Fig. 2B, Supplementary Fig. 1A). This was because iBET-151 
suppressed the epigenetic regulatory function of the BET family 
and affected chromatin remodeling. The genes downregulated by 
iBET-151 were enriched in angiogenesis; cell migration; RAS pro-
tein signal transduction; positive regulation of extracellular sig-
nal-regulated kinase (ERK)-1 and ERK cascade; positive regula-
tion of transcription, DNA-templated; and negative regulation of 
apoptotic process (Fig. 2C, Supplementary Fig. 1B). 
In paclitaxel-treated cells, the upregulated genes were enriched 
in the apoptotic signaling pathway; release of cytochrome c from 
mitochondria; regulation of apoptotic process; and mitochondrial 
electron transport, cytochrome c to oxygen (Fig. 3B, Supplemen-
tary Fig. 1C). Genes downregulated by paclitaxel were enriched in 
sister chromatid segregation, mitotic nuclear division, and centro-
some duplication (Fig. 3C, Supplementary Fig. 1D). According to 
a recent study [16], paclitaxel inhibited mitosis by binding to mi-
crotubules and regulating mitosis-related pathways, including mi-
totic nuclear division, chromosome segregation, and G2/M transi-
tion of the mitotic cell cycle, in lung cancer cells. The results of our 
previous study on lung cancer cells showed that paclitaxel upregu-
lated mitosis-related pathways, including mitotic nuclear division 
and chromosome segregation (unpublished data). 
GO analysis showed a significant increase in the upregulation of 
the same genes involved in the aforementioned pathways in com-
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Table 2. Top 10 downregulated genes in AGS cells treated by iBET-151 and paclitaxel
Gene name Fold change p-value Function
iBET-151
ADGRF1 0.006 0.0116 Cell surface receptor signaling pathway, G-protein coupled receptor signaling pathway
PMEPA1 0.007 0.0362 Cell proliferation, differentiation, apoptosis, motility, extracellular matrix production and immunosuppression
PSG1 0.013 0.015 Defense response
NTM 0.017 0.0002 Neural cell adhesion molecule, cell adhesion
CACNA1H 0.019 0.02405 Regulation of ion transmembrane transport, calcium ion transmembrane transport
SLAMF7 0.021 0.00945 Adaptive immune response, cell adhesion, natural killer cell activation
BMP4 0.025 0.00075 Activation of MAPKK activity
NRP2 0.044 0.00255 Angiogenesis, positive regulation of endothelial cell proliferation
TCF4 0.048 0.00005 Activate transcription
SRC 0.136 0.00005 Epidermal growth factor receptor signaling pathway, signal transduction
Paclitaxel
DOCK10 0.008 0.0147 Regulation of CDC42 activity
ADAP2 0.042 0.0253 GTPase activator activity
SYT1 0.067 0.00405 Calcium ion binding and transporter activity
NREP 0.139 0.0016 Neural function
MEGF11 0.14 0.0136 Retina layer formation, motypic cell-cell adhesion
FAM19A2 0.149 0.04425 Neuronal survival and neurobiological functions
GCNT2 0.168 0.02685 Acetylglucosaminyltransferase activity and N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity
TTYH1 0.187 0.02065 Cell adhesion
RMDN2 0.308 0.0235 Interact with microtubules
NCKAP5 0.31 0.0394 Microtubule depolymerization
Combination
GBP1 0.003 0.04585 GTPase activity
INHBE 0.011 0.0005 Insulin secretion, nerve cell survival, cytokine-cytokine receptor interaction
NUPR1 0.012 0.03795 Positively regulates cell cycle progression
GPX5 0.024 0.0382 Protects cells and enzymes from oxidative damage
DOCK10 0.024 0.01775 Regulation of CDC42 activity
RP1 0.028 0.03635 Microtubule-associated protein regulating the stability and length of the microtubule-based axoneme of photore-
ceptors
PMEPA1 0.029 0.0249 A negative regulator of TGF-beta signaling
GCNT3 0.033 0.0025 Synthesize all known mucin beta 6 N-acetylglucosaminides
SLAMF7 0.034 0.006 Regulation and interconnection of both innate and adaptive immune response
PHF21B 0.034 0.0201 Metal ion binding
bination-treated cells. Moreover, an increase in the upregulation of 
genes involved in reactive oxygen species metabolic process and 
nucleotide-excision repair, DNA damage recognition was ob-
served after combination treatment (Fig. 4B, Supplementary Fig. 
1E). We observed that downregulated genes in the combination- 
and iBET-151-treated cells were enriched in overlapping GO 
terms, including angiogenesis, positive regulation of RAS protein 
signaling, cell migration, MAP kinase activity, and positive regula-
tion of signaling; however, a significant decrease in gene expres-
sion was observed between the combination- and mono-treated 
cells (Fig. 4C, Supplementary Fig. 1F). 
Significantly altered genes in combination-treated cells, 
compared with that in mono-treated cells 
To understand the effects of combination treatment better, we 
identified genes that were more significantly upregulated or down-
regulated in combination-treated cells than in mono-treated cells. 
We first identified the genes with FC >  1.5 and p <  0.05 in com-
bination-treated cells, compared with in control cells. We then 
identified the DEGs with FC >  1.5 in the respective mono-treated 
cells. 
We identified 460 DEGs, including 238 upregulated and 222 
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downregulated DEGs, in AGS cells based on the above-mentioned 
cutoff values. As shown in Fig. 5A, the heatmap of hierarchical clus-
tering of 460 DEGs demonstrated clear discriminating patterns. 
Then, GO analysis demonstrated that combination treatment up-
regulated genes enriched in nucleosome assembly, mitochondrial 
electron transport, and microtubule-based process (Fig. 5B). Sub-
sequent GO analysis after combination treatment showed down-
regulation of genes involved in mitotic sister chromatid segrega-
tion, positive regulation of transcription, positive regulation of 
GTPase activity, and mitotic nuclear division (Fig. 5C). 
Most of these results after combination treatment were similar 
to those obtained after iBET-151 or paclitaxel mono-treatment. 
However, combination treatment induced more changes in the 
genes than those in case of either of the mono-treatments.  
Expression of BET protein target genes and major receptor 
tyrosine kinase  
Next, we determined the mRNA expression levels of BET protein 
target genes. We observed that iBET-151 reduced the mRNA ex-
pression of the oncogenes, MYC and KRAS, and the anti-apoptot-
ic gene, BCL-2. However, no change was observed in the expres-
sion of these genes on paclitaxel treatment, as expected (Fig. 6A). 
In our previous study, we found that iBET-151 induced G1 cell 
cycle arrest (unpublished data). Consistent with this result, the ex-
pression of cyclin dependent kinase-4/6 and E2F transcription fac-
tor-2 involved in G1-S phase transition was reduced. To elucidate 
the underlying biology, we observed the changes in major receptor 
tyrosine kinase (RTK) expression. We confirmed that iBET-151 re-
duced the expression of RTK mRNA and proteins, including 
EGFR, ERBB3, MET, and IGF-1R, thereby regulating cancer cell 
growth and survival. Additionally, RTK expression was further re-
duced on iBET-151‒paclitaxel combination treatment. However, in 
the FGFR family, FGFR-3/4 was significantly increased on iBET-
151 and combination treatments (Fig. 6B and 6C). 
Discussion 
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Fig. 2. DEGs induced by iBET-151 treatment. (A) Volcano plot of DEGs induced in iBET-151–treated versus untreated cells is shown. (B) GO 
biological processes/KEGG pathways upregulated in response to iBET-151 treatment are shown. (C) GO biological processes/KEGG pathways 
downregulated in response to iBET-151 treatment are shown. DEGs, differentially expressed genes; GO, Gene Ontology; KEGG, Kyoto 
Encyclopedia of Genes and Genomes.
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Fig. 3. DEGs induced by paclitaxel treatment. (A) Volcano plot of DEGs induced in paclitaxel-treated versus untreated cells is shown. (B) GO 
biological processes/KEGG pathways upregulated in response to paclitaxel treatment are shown. (C) GO biological processes/KEGG pathways 
downregulated in response to paclitaxel treatment are shown. DEGs, differentially expressed genes; GO, Gene Ontology; KEGG, Kyoto 
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shown. DEGs, differentially expressed genes; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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changes induced by mono- and combined treatments with iBET-
151 and paclitaxel in the AGS GC cell line. First, we confirmed 
that the expression of MYC and BCL-2, which is known as the tar-
get of BRD-4, was decreased on iBET-151 treatment, as expected. 
Interestingly, we observed that KRAS, an oncogene that plays a 
key role in the development and progression of various carcino-
mas, was downregulated in iBET-151–treated cells. Even though 
KRAS has been known as a significant driver in various cancers, it 
has long been considered undruggable. Interestingly, we confirmed 
that KRAS mRNA expression was reduced on iBET-151 treat-
ment and further decreased on iBET-151–paclitaxel combination 
treatment. This result suggested that iBET-151 could be developed 
as an indirect KRAS inhibitor for potential therapeutic effects in 
GC patients. 
Additionally, we confirmed that expression of signal transduc-
tion-related genes, such as epidermal growth factor, vascular endo-
thelial growth factor, IGF, and SRC, was also significantly de-
creased. On the other hand, expression of genes related to chroma-
tin silencing and nucleosome assembly was increased on iBET-151 
treatment. This was because the BET family proteins, the targets 
of iBET-151, are epigenetic regulators. Particularly, expression of 
sirtuin (SIRT)-4 involved in histone deacetylation was significant-
ly increased. SIRT-4 is a tumor suppressor that is reduced in vari-
ous carcinomas, and reduced SIRT-4 protein expression is associ-
ated with poor prognosis. It has also been reported that SIRT-4 in-
terferes with glutamine metabolism and inhibits cell proliferation 
and migration [17]. As mentioned in our previous study, the me-
tabolism pathway is enhanced in not only the iBET-151‒sensitive 
group, but also various carcinomas (unpublished data). Therefore, 
we expected that increasing SIRT-4‒inhibiting glucose pyruvate 
dehydrogenase using iBET-151 would be a feasible therapeutic 
strategy for these cancers. 
Paclitaxel is a drug that binds to tubulin and stabilizes microtu-
bules to suppress mitosis. However, our RNA-seq results revealed 
that paclitaxel also regulates expression of genes involved in cell di-
vision in GC. In this study, expression of genes related to sister 
chromatid segregation, mitotic nuclear division, and centrosome 
duplication was decreased in paclitaxel-treated GC cells. Addition-
ally, expression of genes involved in cytochrome c release in mito-
chondria and apoptotic process was increased. This suggested that 
Fig. 5. DEGs induced by iBET-151–paclitaxel combination treatment. (A) Volcano plot of DEGs induced in combination-treated versus 
untreated cells is shown. (B) GO biological processes/KEGG pathways upregulated in response to iBET-151–paclitaxel combination treatment 
are shown. (C) GO biological processes/KEGG pathways downregulated in response to iBET-151–paclitaxel combination treatment are 
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Fig. 6. Expression of BET protein target genes and major RTK. (A) mRNA expression of BET family protein target and tumor growth-related 
genes is shown. (B) GO biological processes upregulated in response to combination treatment are shown. (C) Validation of DEGs was 
performed by western blotting. BET, bromodomain and extraterminal; RTK, receptor tyrosine kinase; GO, Gene Ontology; DEGs, differentially 
expressed genes; FPKM, fragments per kilobase of exon model per million reads mapped; EGFR, epidermal growth factor receptor; IGF1R, 
insulin-like growth factor receptor 1; IGF2R, insulin-like growth factor receptor 2; FGFR, fibroblast growth factor receptor.
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paclitaxel not only inhibited mitosis by binding to tubulin but also 
regulated mitosis inhibition and apoptosis in cell death by regulat-
ing related gene expression. Therefore, our study provides novel 
findings that may help in identifying appropriate combination 
drugs with paclitaxel for GC treatment via determination of gene 
expression changes induced by paclitaxel. 
Additionally, we found that iBET-151 and paclitaxel separately 
reduced the expression of RTK, which is involved in key signaling 
pathways (RAS/mitogen-activated protein kinase and phospho-
inositide 3-kinase/AKT pathways) that regulate cancer cell prolif-
eration.  
Trastuzumab is approved for use as HER-2‒targeted therapy for 
various cancers, including GC, to improve survival of patients with 
HER-2 amplification. However, in many cases, acquired resistance 
is induced by re-activation due to interaction with other RTKs, 
and this is related to poor survival. We found that iBET-151 re-
duced the expression of other RTKs, such as EGFR, HER-3, and 
MET, which are induce signaling activation by heterodimeric binding 
to HER-2. This expression is further decreased on iBET-151-pacli-
taxel combination treatment. Therefore, the combination of iBET-
151 and paclitaxel can overcome resistance induced by HER-2-tar-
geted treatment in GC. 
JQ1, a BET inhibitor, has been recently reported to induce resis-
tance by increasing FGFR protein expression in ovarian cancer 
[18] and uveal melanoma [19], but the underlying mechanism re-
mains unclear. In our results, FGFR-3 protein expression was in-
creased in GC, and RNA-seq showed that FGFR-3 and FGFR-4 
mRNA expression was increased. Further research is needed to 
elucidate FGFR-3 regulation, but this makes it possible to find out 
that FGFR3 is regulated at the transcription level by the BET in-
hibitor. Therefore, our results show that not only JQ1 but also 
iBET-151 increased FGFR-3 expression, and in particular iBET-
151 regulates FGFR3 at the mRNA level. Therefore, our results 
add evidence for combination therapy with BET inhibitor and 
FGFR inhibitor. 
In our previous study, iBET-151 and paclitaxel exerted synergis-
tic effects on GC cell proliferation and migration (unpublished 
data). Using RNA-seq analysis, we found that combination-treated 
cells showed higher changes in gene expression in the above-men-
tioned pathways than untreated and mono-treated cells. AGS cells 
showed the greatest reduction in angiogenesis-related expression 
of vascular endothelial growth factor-A, matrix metalloprotein-
ase-14, and X-box-binding protein (XBP)-1 in response to combi-
nation treatment, compared with to either iBET-151 or paclitaxel 
single treatment. Particularly, XBP-1, a transcription factor, is 
known to promote not only angiogenesis, but also tumorigenesis, 
proliferation, and drug resistance. 
In conclusion, we analyzed the biological functions induced by 
iBET-151–paclitaxel combination treatment. The results elucidat-
ed the biological mechanism underlying the synergistic effects of 
iBET-151 and paclitaxel. More research is needed in the future to 
determine the exact mechanisms underlying the action of these 
compounds, but we expect that the combination therapy of iBET-
151 and paclitaxel will be a promising therapeutic strategy for GC. 
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